All In MedTech

FDA Clearance Tracker · P130008-S093

Inspire II Upper Airway Stimulator

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 16, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 16, 2022

Approved

Time to decision

28 days

Received Nov 18, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P130008-S093
Device name
Inspire II Upper Airway Stimulator
Applicant location
Maple Grove, MN
Received
Nov 18, 2022
Decided
Dec 16, 2022
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P130008

Device type

Device class
Class III

Every decision under product code MNQ

FDA's approval statement

As written in FDA's record.

Approval for the Inspire® Upper Airway Stimulation (UAS). The device is indicated for use to treat a subset of patients with moderate to severe obstructive sleep apnea (OSA) (apnea-hypopnea index [AHI] of greater than or equal to 15 and less than or equal to 65). Inspire® UAS is used in adult patients 22 years of age and older who have been confirmed to fail or cannot tolerate positive airway pressure (PAP) treatments (such as continuous positive airway pressure [CPAP] or bi-level positive airway pressure [BPAP] machines) and who do not have a complete concentric collapse at the soft palate level.PAP failure is defined as an inability to eliminate OSA (AHI of greater than 15 despite PAP usage), and PAP intolerance is defined as:1) Inability to use PAP (greater than 5 nights per week of usage; usage defined as greater than 4 hours of use per night); or2) Unwillingness to use PAP (for example, a patient returns the PAP system after attempting to use it).Inspire® UAS is also indicated for use in patients between the ages of 18 and 21with moderate to severe OSA (15?AHI?65) who:1) Do not have complete concentric collapse at the soft palate level;2) Are contraindicated for, or not effectively treated by, adenotonsillectomy;3) Have been confirmed to fail, or cannot tolerate, PAP therapy despite attempts to improve compliance; and4) Have followed standard of care in considering all other alternative/adjunct therapies.

Source documents

Other decisions for Inspire Medical Systems

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.